Cervical cancer is associated with human papilloma virus infection. However, this infection is insufficient to induce transformation and progression. Loss of heterozygosity analyses suggest the presence of a tumor suppressor gene (TSG) on chromosome 6p21.3-p25. Here we report the cloning NOL7, its mapping to chromosome band 6p23, and localization of the protein to the nucleolus. Fluorescence in situ hybridization analysis demonstrated an allelic loss of an NOL7 in cultured tumor cells and human tumor samples. Transfection of NOL7 into cervical carcinoma cells inhibited their growth in mouse xenografts, confirming its in vivo tumor suppressor activity. The induction of tumor dormancy correlated with an angiogenic switch caused by a decreased production of vascular endothelial growth factor and an increase in the production of the angiogenesis inhibitor thrombospondin-1. These data suggest that NOL7 may function as a TSG in part by modulating the expression of the angiogenic phenotype.
Introduction
With approximately 470 000 new cases annually, cervical cancer (CC) is the most common gynecologic malignancy worldwide and is one of the leading causes of death in women (Cannistra and Niloff, 1996) . Infection with the human papilloma virus (HPV) is closely associated with disease and recent reports have found that essentially all cases of CC demonstrate the presence of the virus (Walboomers et al., 1999) . However, experimental evidence has shown that the presence of high-risk HPV is not sufficient to induce transformation and progression (Chen et al., 1993; Montgomery et al., 1995; Uejima et al., 1995) .
Most types of cancer develop in a multi-step fashion in which there is a sequential activation of oncogenes and inactivation of tumor suppressor genes (TSG) in the same clone of cells. These genetic changes generate concomitant phenotypic changes in the tumor cells that allow them to survive and expand. A number of potential CC-associated TSG have been identified (Lazo, 1999; Wolf and Ramirez, 2001 ). In addition, chromosomal loss of heterozygosity (LOH) has been consistently observed, including on the short arm of chromosome 6 (6p), suggesting the presence of one or more TSG. Detailed allelotype studies have indicated potential sites of TSG at 6p23, 6p21.3, and 6p25 in CC (Mitra et al., 1994; Mullokandov et al., 1996; Huettner et al., 1998; Kersemaekers et al., 1998; Rader et al., 2000) . However, the identity of the TSG located on this region of 6p has remained elusive.
Here we report the cloning of a new gene, NOL7, and locate it to chromosome band 6p23. In addition, we demonstrate that there is allelic loss of NOL7 in both CC cell lines as well as fresh tumor samples. Transfection of NOL7 into CC cells inhibited their growth in mouse xenografts, confirming that this nucleolar protein product functions as a TSG in human CC. Finally, we functionally demonstrate that the induction of tumor dormancy is caused in part by a switch in the angiogenic phenotype of the NOL7-transfected cells, which was the result of a decrease in the production of the angiogenic vascular endothelial cell growth factor (VEGF), as well as an increase in the production of the naturally occurring inhibitor of angiogenesis thrombospondin-1 (TSP-1). These data suggest that this novel nucleolar protein may function as a TSG in part by modulating the expression of the angiogenic phenotype in CC.
Results

Cellular and chromosomal localization of NOL7
While seeking to identify genes that were differentially expressed in endothelial cells under different conditions, we recently cloned NOL7, a gene encoding an mRNA of 902 base pairs and a protein with a predicted molecular weight of 27 kDa that bore no significant homologies to any known family of genes (accession number NM_016167). Northern blot analysis of commercially available human tissue blots demonstrated that NOL7 was expressed in a number of different tissue types throughout the body and was particularly prevalent in the adrenal gland, thyroid gland, heart, skeletal muscle, and kidney (data not shown).
In order to determine the cellular localization of the NOL7 protein, we transiently transfected Cos7 cells with GFP-tagged full-length NOL7. The chimeric protein localized to the nucleus of the cells, particularly to the nucleolus (Figure 1 ). The nucleolar localization of NOL7 was confirmed by immunocytochemistry using an antibody that was specific for B23, another independent nucleolar marker (Figure 1 ). In addition, three independent BAC clones containing sequences from the NOL7 gene were hybridized to normal metaphase cells in order to determine the chromosomal location of NOL7. All three clones hybridized to the same chromosome locus, which diamidino-phenylindole (DAPI) banding identified as chromosome 6, band p23 (Figure 2a and b) . This mapping has been confirmed in subsequent experiments using a chromosome 6-centromere-specific probe in combination with the BAC clones.
Allelic loss of NOL7 in CC cell lines and human tumor samples LOH on the short arm of chromosome 6 (6p) is frequently observed in CC, suggesting the presence of one or more TSG on this chromosomal arm (Mitra et al., 1994; Mullokandov et al., 1996; Huettner et al., 1998; Kersemaekers et al., 1998; Rader et al., 2000) . To determine if NOL7 might be one of these suppressor genes, we initially determined levels of its mRNA expression in CC cell lines. Northern blot analysis of eight independent human CC cell lines showed a decrease in NOL7 mRNA in three of the eight cell lines (Figure 3 ). This proportion of 38% is consistent with previous findings that approximately 40% of CCs demonstrate a LOH for 6p23 (Rader et al., 2000) .
Seeking to define the deletion pattern of the NOL7 gene in tumor cell lines as well as in fresh tumor samples, we made use of a smaller 8-kb genomic probe containing the entire NOL7 gene, in combination with a chromosome 6-centromere-specific probe ( Figure 4 , Table 1 ). In all, 600 interphase cells from three different lymphocyte preparations showing two distinct signals for the control probe were scored as normal controls to define the cutoff values for NOL7 deletion. The threshold for detection of the NOL7 gene deletion was set to 22.4%, defined by the mean plus three standard deviations of the percentage of nuclei showing only one NOL7 gene signal and two signals for the control probe. For the Ca Ski cell line, the Cep6 control probe exhibited five copies of the centromeric region of chromosome 6. Two of these five signals hybridized on identical short derivatives of chromosome 6. Rearrangements involving the entire short arm of chromosome 6 could explain the absence of NOL7 signal. A deletion of one or two NOL7 signals on the three remaining copies of chromosome 6 Cervical cancer tumor suppressor gene inhibits angiogenesis R Hasina et al was observed in 90% of interphase nuclei (Table 1) . The BAC clone RPCI1-55N8 did not demonstrate a signal pattern deletion in the ME-180 cell line (Figure 4) . However, when hybridized with an 8-kb NOL7-specific probe, both the ME-180 and SiHa cell lines demonstrated abnormal signal patterns in 92 and 81% of the interphase nuclei, respectively.
The same 8-kb NOL7 genomic probe was hybridized to interphase nuclei from three consecutive CC-derived tissue samples. Their overall ploidy was determined using the Cep6 centromeric probe. Patient 1 showed a high percentage (34%) of nuclei with one Cep6 control signal associated with only one NOL7 signal (Figure 4 ). When two control signals were counted, the NOL7 gene was deleted in 28% of nuclei. Overall, 62% of cells exhibited an abnormal NOL7 profile. Patients 2 and 3 showed a similar pattern, with 43 and 44% of diploid cells (two Cep6 signals) having loss of one NOL7 signal (Figure 4 ). In all, 25 and 11% of nuclei exhibited a hyperdiploid pattern (three and four Cep6 signals), where the NOL7 gene was always deleted with loss of one, two or three signals. Overall, for patients 2 and 3, 79 and 63% of interphase nuclei demonstrated a loss of NOL7 signals, respectively. To determine whether the high number of nuclei with one Cep6 signal (patient 1) was due to an aneuploid pattern or chromosome 6 abnormalities, we hybridized all patient samples with a centromeric chromosome 12 probe (data not shown). This probe was selected because chromosome 12 was not reported as frequently implicated in chromosomal aberrations of CC (Mitra et al., 1994) . Hybridization results confirmed that patient 1 had a diploid pattern, with 93% of cells exhibiting two Cep12 probe signals. A diploid profile associated with a clonal evolution toward Figure 4 Demonstration of allelic loss of NOL7 in cervical carcinoma cell lines and human tumors. FISH experiments were performed on: (a) ME-180 CC cell line hybridized with the RPCI1-55N8 BAC clone; (b, c) ME-180 and SiHa CC cell lines hybridized with an 8-kb NOL7 gene-specific probe; and (d-f) three consecutive CC samples hybridized with the 8-kb NOL7 genomic probe. NOL7 probes were labeled with bio-11-dUTP, and detected with FITC. NOL7 probes were cohybridized with Spectrum Orange directly labeled probe for the centromere of chromosome 6 (Cep6). Experiments demonstrate loss of at least one NOL7 allele in both the tumor cell lines as well as the tumor samples. Cervical cancer tumor suppressor gene inhibits angiogenesis R Hasina et al a tetraploid pattern was found in patients 2 and 3. These results indicate that the high frequency of Cep6 probe loss was probably due to a rearrangement involving the entire chromosome 6 (monosomy) or due to a chromosome 6 short arm aberration, including the pericentromeric Cep6 locus (6p11-6q11).
Suppression of in vivo tumor growth by NOL7
In order to test the hypothesis that NOL7 is able to function as a tumor suppressor in cervical mucosa, the full-length NOL7 cDNA was cloned into the pcDNA3.1/V5-His-TOPO. vector and stably transfected into SiHa cells. As a negative control, the LacZ gene was also cloned into the pcDNA3.1/V5-His-TOPO vector and stably transfected into SiHa cells. Individual clones were selected, ring-cloned and expanded from individual 100 mm dishes. Expression of the transfected NOL7 was confirmed via Western blot analysis using an antibody for the V5 tag ( Figure 5a ). In vitro proliferation assays were performed in order to determine if the introduction of NOL7 into CC cells would alter their proliferation profile. The NOL7-containing SiHa clones proliferated at a rate that was similar to both the parental SiHa cell line as well as the LacZ-containing SiHa clones (Figure 5b ), suggesting that the introduction of NOL7 into the tumor cells had no effect on their in vitro proliferation. However, the subcutaneous injection of NOL7-containing SiHa clones into nude mice garnered significantly different results. Tumorigenicity was significantly reduced in the NOL7 clones when compared to the parental cell line or the LacZ-containing SiHa cells ( Figure 5c ).
NOL7 represses the angiogenic phenotype by modulating the expression of VEGF and TSP-1
The observation that the introduction of NOL7 into CC cells altered their in vivo, but not in vitro, growth characteristics suggested that the expression of this gene might contribute to the regulation of the angiogenic phenotype. To determine if the induction of tumor dormancy in the NOL7-containing cells was related to a switch in the angiogenic phenotype, we first evaluated the rates of proliferation and apoptosis as well as the microvessel density of the tumor xenografts. The NOL7 tumors as well as the parental and LacZ tumors were found to contain both proliferating cells ( Figure 6 ) as well as cells undergoing apoptosis ( Figure 6 ). However, while the proliferation indices of the three cell types were similar, the apoptotic index of the NOL7-containing cells was much greater (Table 2 ). This suggested that the inability of the NOL7-containing tumor cells to grow beyond a certain threshold in size was not due to a lack of tumor cell proliferation. Rather, it was likely due to a balance in the rate of proliferating cells and cells undergoing apoptosis. To reveal microvessels, tumor sections were stained for CD31, a marker that is expressed on endothelial cells. Rare CD31-positive staining vessels were found scattered within the dormant NOL7 tumors ( Figure 6 , Table 2 ). Conversely, a robust angiogenic response, as determined by CD31 positivity, was observed in the parental and LacZ clones ( Figure 6 , Table 2 ). The combined findings of an imbalance in the rates of proliferation/apoptosis as well as altered microvessel densities suggest that one of the mechanisms by which NOL7 acts as a tumor suppressor may be by causing a switch in the angiogenic phenotype.
Whether or not angiogenesis occurs depends on the relative levels of inducers and inhibitors of neovascularization present within the microenvironment surround- Figure 5 Tumor formation of CC cells transfected with NOL7 in nude mice. (a) Stable independent clones of the SiHa cell line expressing the full-length NOL7 cDNA were generated and verified via Western blot using an antibody to the V5 sequence tag present in the vector; (b) in vitro proliferation of SiHa parental, LacZ, and NOL7 clones; (c) in vivo tumor growth of SiHa parental, LacZ, and NOL7 transfected cells inoculated in nu/nu mice and monitored over a period of 49 days (n ¼ 12 animals per group). The in vitro proliferation of the three cell types was similar, while the in vivo tumor growth of the NOL7-transfected cells was significantly decreased when compared to the SiHa-and LacZ-containing cells.
ing the endothelial cells. To better define the mechanism of the angiogenic switch observed in in vivo tumor xenografts, serum-free conditioned media (CM) from the parental as well as NOL7 and control LacZ clones were collected and assayed for their ability to stimulate angiogenesis in vitro using the endothelial cell migration assay. CM from the parental cell line as well as the LacZ SiHa clones strongly stimulated endothelial cell migration ( Figure 7) . However, CM from the NOL7-transfected SiHa clones had a significantly reduced Figure 6 Histological analysis of SiHa parental and NOL7 tumor xenografts. SiHa parental and NOL7-transfected cells were injected s.c. in nude mice. After 7 weeks tumors were resected and prepared for histology. The histological sections were stained with H&E ( Â 25) or stained for proliferating cells (anti-PCNA, Â 400), apoptotic cells (cleaved caspase-3, Â 400), and microvessel density (anti-CD31, Â 400). The SiHa parental and NOL7 cells had a similar rate of proliferation, while the NOL7 transfectants had a higher degree of apoptosis and lower microvessel densities. ability to stimulate endothelial cell migration. In addition to having a decreased capacity to induce endothelial cell migration, the CM from the NOL7 clones contained high levels of one or more molecules that were capable of inhibiting angiogenesis. When the NOL7 CM was mixed 1:1 with media from either the parental or the LacZ clones, it was able to block angiogenesis, as measured by the in vitro endothelial cell migration assay (data not shown). These results suggest that a switch from an angiogenic to an angioinhibitory phenotype is one of the potential mechanisms by which the introduction of NOL7 into the SiHa CC cell line resulted in a change in the angiogenic status. We subsequently performed genomic profiling on the SiHa parental and NOL7 clones in order to obtain global signatures of angiogenesis-related genes whose expression might be altered by introduction of NOL7. The expression data demonstrated that transfection of NOL7 into the parental cells resulted in an upregulation of TSP-1 and a concomitant downregulation of VEGF (please see supplemental material). In order to validate these findings, we performed Western blot analyses for VEGF and TSP-1 on CM from the parental SiHa and the NOL7-containing cells. The CM from the parental SiHa tumor cells contained high levels of VEGF and extremely low levels of TSP-1 (Figure 8a) , while the NOL7 transfectants demonstrated a decreased expression of VEGF and an increased expression of TSP-1. Similarly, we performed immunohistochemistry for VEGF and TSP-1 on the SiHa parental and the NOL7-containing tumor xenografts. The SiHa parental tumors demonstrated high levels of VEGF expression In vitro angiogenic activity of parental and NOL7-transfected SiHa cells. Serum-free CM from parental SiHa, LacZ, and NOL7-transfected clones were functionally tested for their ability to stimulate endothelial cell migration. CM alone from the SiHa parental and the LacZ clones (open bars) strongly stimulated endothelial cell migration in a fashion similar to VEGF alone, while the NOL7 clones demonstrated a significant reduction in the stimulation of migration. In addition, CM from the NOL7 clones were able to inhibit the induction of endothelial cell migration by VEGF (filled bars), suggesting that these cells were secreting a protein that had angioinhibitory activity. and low levels of TSP-1 in vivo (Figure 8b) . Conversely, the NOL7 clones expressed markedly reduced amounts of VEGF and considerably higher levels of TSP-1 than parentals in vivo (Figure 8c) .
In order to determine if the altered levels of VEGF and TSP-1 were biologically important for the angiogenic switch observed in the NOL7 clones, we performed additional in vitro endothelial cell migration assays using serum-free CM with neutralizing antibodies to either VEGF or TSP-1 (Figure 8c ). As anticipated, the angiogenic activity of the parental and LacZ clones was due primarily to the secretion of VEGF, because neutralizing antibodies to VEGF reduced the ability of the CM from these cells to induce the migration of endothelial cells. The combination of CM and anti-VEGF resulted in a 60% reduction in the ability of CM from either the SiHa parental or the LacZ clones to induce endothelial cell migration. However, anti-VEGF did not alter the migration profile of the NOL7 clones. This observation is in keeping with our in vivo findings that the NOL7-containing clones express low levels of VEGF, while the parental and LacZ clones express high levels of this cytokine. Conversely, the antiangiogenic activity of the NOL7 clones was due primarily to the secretion of TSP-1. The addition of TSP-1-neutralizing antibody to the NOL7 CM relieved the inhibitory activity present in the CM from the NOL7 clones, while addition of anti-TSP-1 had no effect on the SiHa parental or LacZ clones (Figure 8c ).
Discussion
CC continues to be a major worldwide health problem. HPV is recognized as a major contributor to the development of CC. It is now well established that high-risk HPVs containing the E6 and E7 viral genes can disrupt the cell cycle by altering the function of the p53 and Rb TSG (Lazo, 1999; Wolf and Ramirez, 2001) . HPV E6 induces rapid degradation of p53 via ubiquitindependent proteolysis. Similarly, HPV E7 complexes with the hypophosphorylated form of Rb, causing its proteolysis via the proteosome pathway. However, there are still many aspects regarding the molecular mechanisms of CC that remain unanswered, such as the identity of other genetic alterations required for CC progression. A number of TSG have been postulated to play a role. Here we have provided functional in vitro and in vivo evidence that NOL7 is the candidate TSG located at 6p23. Northern blot analysis demonstrated a decreased expression of NOL7 mRNA in approximately 40% of CC cell lines. Furthermore, FISH analysis revealed an allelic loss of NOL7 in cultured tumor cells and human tumor samples. Transfection of NOL7 into CC cells inhibited their growth in mouse xenografts, confirming its in vivo tumor suppressor activity. Finally, the induction of tumor dormancy correlated with an angiogenic switch caused by decreased production of VEGF and an increase in the production of the angiogenesis inhibitor TSP-1.
Traditionally, the nucleolus has been considered to be a subnuclear zone whose sole function was related to ribosomal transcription and subunit assembly. Recent findings have suggested that the nucleolus may play an important additional role in a number of physiologic and pathologic processes such as regulation of cell cycle, apoptosis, aging, and cancer biology (Olson et al., 2000; Visintin and Amon, 2000) . For example, NOL8, another novel nucleolar protein, was recently reported to act as an oncogene in diffuse-type gastric carcinomas (Jinawath et al., 2004) . Conversely, the p14 ARF TSG protein was initially characterized as such for its ability to inactivate mdm2, the negative regulator of the p53 transcription factor, by relocalizing it to the nucleolus (Weber et al., 1999) . In addition, it has recently been shown that p14 can also act as a tumor suppressor by inhibiting ribosomal RNA processing by retarding processing of 47/45S and 32S precursors (Sugimoto et al., 2003) . To our knowledge, this is the only other known TSG whose protein product localizes to the nucleolus.
Whether or not angiogenesis occurs in a particular tissue depends upon the balance between the relative amounts of molecules that induce and molecules that inhibit angiogenesis (Bouck et al., 1995) . In normal tissues, blood vessels are usually quiescent and cells secrete low levels of inducers and high levels of inhibitors. As normal cells progress towards malignancy, they must develop the ability to induce angiogenesis. In order to achieve this switch, tumor cells increase the amount of inducers and decrease the amount of inhibitors they secrete. There is considerable interest in determining how cells, progressing from normal to tumorigenic, switch from being antiangiogenic to angiogenic. In some animal models, a distinct switch to the angiogenic phenotype is seen (Hanahan and Folkman, 1996) . In other cases, the cells developing into tumors sequentially become more angiogenic in a stepwise fashion (Lingen et al., 1997; Volpert et al., 1997) . The exact mechanisms regarding how this occurs in most neoplasms have for the most part remained elusive. However, a growing body of evidence suggests that the activation of oncogenes as well as the inactivation of TSG play an important role in this phenotypic switch. For example, expression of VEGF can be stimulated by various oncogenic stimuli such as ras, v-src, c-fos, and c-jun (Mukhopadhyay et al., 1995; Rak et al., 1995; Kraemer et al., 1999; Marconcini et al., 1999) . Similarly, inactivation of the p53, VHL, and RB2/p130 TSG results in increased VEGF production (Mukhopadhyay et al., 1995; Gnarra et al., 1996; Claudio et al., 2001) . Conversely, activation of oncogenes such as c-jun, v-myc, v-src, and ras, or the inactivation of the p53, Rb, PTEN, and nm23 TSG, results in a decreased expression of TSP-1 (Dameron et al., 1994; Slack and Bornstein, 1994; Zabrenetzky et al., 1994; Gnarra et al., 1996; Sheibani and Frazier, 1996; Tikhonenko et al., 1996; Dejong et al., 1999; Wen et al., 2001; Watnick et al., 2003) . Data presented here show that NOL7, like p53, can modulate both sides of the angiogenic balance by increasing the expression of TSP-1 and decreasing the expression of VEGF. However, since p53 is inactivated as a result of HPV infection in CC, and is functionally inactivated via degradation in the SiHa cell line used in these experiments (Yaginuma and Westphal, 1991; Srivastava et al., 1992) , the modulations of both VEGF and TSP-1 by NOL7 appear to be p53-independent events in CC. It is also interesting to note that the oncogenic stimulus of hepatocyte growth factor (HGF) modulates VEGF and TSP-1 in the opposite fashion (Zhang et al., 2003) in other tumor types. Therefore, it is possible that overexpression of HGF in conjunction with the loss of NOL7 in CC may represent a coordinated TSG/ oncogene switch that contributes to the induction of the angiogenic phenotype in CC. However, to our knowledge, the expression of HGF has not been thoroughly investigated in the setting of CC. Similarly, detailed analyses of the potential role for other TSG/ oncogenes in the modulation of VEGF and TSP-1 in the context of CC have not been performed to date. Further investigations into these possibilities are warranted.
At this time, the status of the second NOL7 allele is undetermined. From preliminary RTQ-PCR experiments, we do know that the parental cell lines of Ca Ski, ME-180, and SiHa continue to produce NOL7 mRNA. However, NOL7 expression in the parental cells is approximately 60% less than a number of different normal cell types containing two NOL7 alleles (data not shown). Therefore, it is possible that the loss of function is due to a mutation of the remaining allele or the result of haplo-insufficiency. We are presently investigating this issue, as well as determining when during the carcinogenic process the allele is lost. We also do not know what the incidence of NOL7 inactivation in other malignancies may be. A deletion of 6p23 has been observed in a number of different types of myeloid and lymphoid malignancies (Nagai et al., 1999; Chen et al., 2000; Nakase et al., 2000; Takeshita et al., 2004) . However, to our knowledge, data regarding a detailed cytogenic analysis of the short arm of chromosome 6 in other malignancies are limited. Finally, it is presently unknown if alterations in NOL7 are the consequence of biological selection for specific chromosomal locations containing integrated HPV DNA or the result of other independent genetic changes also essential for the development of malignancy. Further investigation into these and other questions will provide additional information about this novel nucleolar candidate TSG. However, our findings support the hypothesis of an increasingly complex role of the nucleolus in a wide range of physiologic and pathologic conditions, including cancer.
Methods
Cells
The human cervical carcinoma cell lines SiHa, Ca Ski, C-33A, AN3 CA, ME-180, HEC-1-A, C-4 I, and HeLa cell lines were obtained from the ATCC. The SiHa and Ca Ski cell lines were cultured in RPMI and 10% FBS. The C-33A and AN3 CA cell lines were cultured in Eagle's Minimal Essential Medium with 10% FBS. ME-180 and HEC-1-A cell lines were cultured in McCoy's 5A medium with 10% FBS. The C-4 I cell line was cultured in Waymouth's 752/1 medium with 10% FBS. The HeLa and Cos7 cell lines were cultured in DMEM with 10% FBS. All cells were cultured at 371C in a 5% CO 2 -95% air environment in humidified incubators. All media and reagents were purchased from Invitrogen (Carlsbad, CA, USA).
Serum-free CM was generated by rinsing the cells with PBS once, RPMI three times, incubating them in RPMI for 4 h, refeeding them with RPMI and collecting the CM 48 h later. The CM were concentrated and dialysed using Centriprep-3 concentrators (Amicon Inc., Beverly, MA, USA). Protein concentrations were determined using the Coomassie Protein Assay Reagent 23200 (Pierce Biomedical Company, St Louis, MO, USA).
mRNA Isolation and Northern blots mRNA was isolated with Oligotex Direct mRNA Mini Kit (Qiagen, Valencia, CA, USA). In all, 2 mg of denatured RNA was loaded onto a formaldehyde agarose gel and blotted onto a GeneScreen Plus membrane (NEN Life Science/PerkinElmer, Boston, MA, USA). The membrane was hybridized with the [alpha-32 P]dATP-labeled (Amersham, Piscataway, NJ, USA) NOL7 probe at 681C for 1 h.
Chromosomal localization
The human RPCI1 BAC library in the vector pCYPAC2, with an average insert size of 110 kb, was obtained from the UK HGMP Resource Centre (Cambridge, UK) and screened to obtain NOL7-specific genomic probes. Three gene-specific positive individual clones, 223-E5, 80-J10, and 113-O18, were identified on the filters. The clones were obtained from the HGMP Resource Centre, DNA was extracted with the QiaFilter Maxi DNA extraction kit (Qiagen, Valencia, CA, USA) and their gene specificity was confirmed by Southern blot. FISH was performed according to standard protocols as described previously (Coignet et al., 1999) . Briefly, the probes were labeled by nick translation with digoxigenin-11-deoxyuridine triphosphate (Roche, Indianapolis, IN, USA). Competition hybridization by preannealing with a 100-200-fold excess of Cot-1 DNA (Invitrogen, Carlsbad, CA, USA) was performed before overnight hybridization to normal cells complement chromosome with previously denatured DNA. Probes were visualized by incubation with sheep antidigoxigenin-fluorescein isothiocyanate (FITC) (Roche, Indianapolis, IN, USA). Cells and chromosomes were counterstained with DAPI and embedded in Vectashield (Vector Laboratories, Burlingame, CA, USA).
Generation of probes for FISH LANL Human Single Chromosome Library on chromosome 6, LA06NC01 was obtained from UK HGMP Resource Centre (Cambridge, UK). Four positive clones LA0634c7, LA0655n13, LA0658k18, and LA0668j14 were identified. Clone LA0634c7 was used to generate an NOL7-specific genomic DNA probe by PCR. Briefly, cosmid DNA extracted from clone LA0634c7 was used as template to generate an 8-kb PCR product by the Platinum Pfx DNA Polymerase kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The forward and reverse primers were ggt gct gtt gct gat gtg ggt atg and tct ttg atg tgt atg gtt ggt t. This 8-kb product was subsequently used as a probe for FISH on CC cell lines and human patient samples. Spectrum Orangedirectly labeled centromere probes specific for chromosome 6 (CEP 6-D6Z1) and chromosome 12 (CEP 12) (Vysis, Downers Grove, IL, USA) were used in the FISH experiments as control probes.
Fluorescence in situ hybridization Metaphase preparations and single-cell suspensions obtained from fresh tumors were fixed in acetic acid/methanol (1:3) solution. The different probes were labeled by nick translation (BioNick, Invitrogen, Carlsbad, CA, USA) with biotin-11-deoxyuridine triphosphate (Invitrogen, Carlsbad, CA, USA). Biotinylated probes were visualized by subsequent incubations with (i) streptavidin-FITC (Vector Laboratories, Burlingame, CA, USA), (ii) biotinylated goat anti-streptavidin (Vector Laboratories, Burlingame, CA, USA), and (iii) streptavidin-FITC (Vector Laboratories, Burlingame, CA, USA). Cells and chromosomes were counterstained with DAPI and embedded in Vectashield (Vector Laboratories, Burlingame, CA, USA). Digital images were captured using a cooled-coupled device (CCD) camera (Photometrics, Tucson, AZ, USA) mounted on an Axioplan fluorescence microscope (Zeiss, Oberkochen, Germany) equipped with selective filters for fluorescein, rhodamine, and DAPI, and controlled by a G3 Macintosh computer with SmartCapture (Digital Scientific, Cambridge, UK) and MacProbe softwares (PSI/Applied Imaging, San Jose, CA, USA). In all cases, a minimum of 20 metaphases and 200 interphase nuclei were analysed. FISH was performed as described previously (Coignet et al., 1999) . Cell lines were cultured and harvested for chromosome preparation. Fresh tumor tissue, acquired with Institutional Review Board approval under the exemption status, was lacerated and digested overnight with Collagenase (1 mg/ml, Sigma, St Louis, MO, USA) and Hyaluronidase (100 mg/ml, Sigma, St Louis, MO, USA). Metaphase preparations and single-cell suspensions from fresh tumors were fixed in acetic acid/methanol (1:3) solution. The probes were labeled by nick translation with biotin-11-deoxyuridine triphosphate (BioNick, Invitrogen, Carlsbad, CA, USA). Competitive hybridization was performed by preannealing the denatured DNA with a 100-200-fold excess of Cot-1 DNA (Invitrogen, Carlsbad, CA, USA) before overnight hybridization. Biotinylated probes were visualized by subsequent incubations with (i) streptavidin-FITC, (ii) biotinylated goat antistreptavidin, and (iii) streptavidin-FITC (all from Vector Laboratories, Burlingame, CA, USA). Cells and chromosomes were counterstained with DAPI and embedded in Vectashield (Vector Laboratories, Burlingame, CA, USA). In all cases, a minimum of 20 metaphases and 200 interphase nuclei were analysed.
Cellular localization
A GFP-NOL7 fusion protein was generated using the GFP Fusion TOPO TA Cloning kit (Invitrogen, Carlsbad, CA, USA). Briefly, the full-length NOL7 cDNA was ligated into the plasmid vector pcDNA3.1/NT-GFP-TOPO, and the cloning reaction was transformed into chemically competent cells provided in the kit. A total of 10 colonies were selected, the DNA was purified with Qiagen Plasmid Mini kit (Qiagen, Valencia, CA, USA), and sequenced for verification of insert orientation. Cos7 cells were plated in duplicate wells of LabTek chamber glass slides at a density of 10 5 cells/ml and cultured overnight. The cells were transiently transfected using the CaPO 4 Transfection Kit (Invitrogen, Carlsbad, CA, USA), following the manufacturer's protocol. Briefly, cells were treated with CaPO 4 solution containing 20 mg/ml GFP-NOL7 fusion protein for 4 h. After 24 h, positive NOL7 transfectants were identified by their green fluorescence. Nuclei were counterstained with DAPI. In addition, cells were fixed with 4% paraformaldehyde for 10 min, rinsed with PBS, permeabilized with 0.2% Triton X-100 in PBS for 10 min, followed by a solution of 2% bovine serum albumin (BSA)/2% normal goat serum in PBS for 10 min. The goat primary anti-B23 (C-19) antibody (Santacruz, Santa Cruz, CA, USA; Catalog #: SC-6013, 1:250 dilution) was incubated on the slide in a moisture chamber for 1 h. Bovine anti-goat IgG-R secondary antibody (Santacruz, Santa Cruz, CA, USA; Catalog #: SC-2349; 1:250 dilution) was then applied for 30 min. Fluorescence images were obtained using an Axiovert 200 M inverted microscope (Carl Zeiss, Oberkochen, Germany), with a Hamamatsu Orca ER camera (Opelco, Dulles, VA, USA) and Openlab capturing software (Improvision, Lexington, MA, USA).
NOL7 transfection into CC tumor cells NOL7-expressing CC tumor cell lines were generated by cloning the full-length cDNA into the HindIII/XbaI sites of the expression vector pcDNA3.1/V5-His-TOPO. (Invitrogen, Carlsbad, CA, USA). The final product was amplified by PCR, and the construct was sequenced to confirm orientation. At 24 h before transfection, the cells were seeded in 100 mm plates so that they would reach approximately 80% confluency by the next morning. Transfections were performed using calcium phosphate according to the manufacturer's protocol, using 20 mg DNA and selecting for 2-3 weeks using neomycin (Invitrogen, Carlsbad, CA, USA; 300 mg/ml). Individual clones were picked via ring cloning and transferred into six-well plates, grown and expanded as required.
Western blot of NOL7
Western blots were conducted according to the protocol provided with the antibodies. Briefly, whole-cell lysates were separated on a 12% SDS-PAGE gel and blotted onto Immunoblot-PVDF membrane (Bio-Rad, Hercules, CA, USA). The blot was blocked and then incubated with 1:3000 Anti-V5 antibody (Invitrogen, Carlsbad, CA, USA), followed by 1:5000 anti-mouse antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After washing with TBS-Tween, the blot was incubated in ECL reagents (Amersham, Piscataway, NJ, USA), followed by exposure to film.
Western blot for VEGF and TSP-1 Serum-free CM from the SiHa-and NOL7-containing clones were separated on 12% (VEGF) and 5% (TSP-1) SDS-PAGE gels and blotted onto immunoblot-PVDF membrane (BioRad, Hercules, CA, USA). The blot was blocked and then incubated with 1:200 anti-VEGF antibody (Santa Cruz, Santa Cruz, CA, USA; Catalog #: SC-152) or 1:200 anti-TSP-1 (Santa Cruz, Santa Cruz, CA, USA; Catalog #: SC-12312) followed by 1:2500 anti-rabbit (for VEGF Western) or antigoat (for TSP-1 Western) antibodies (Santa Cruz, Santa Cruz, CA, USA). After washing with TBS-Tween, the blot was incubated in ECL reagents (Amersham, Piscataway, NJ, USA) followed by exposure to film.
In vivo tumor studies Female 3-4-week-old nu/nu mice were used. Mice (Charles River Laboratories, Wilmington, Maine, USA) were acclimated and caged in groups of four or less. Cervical carcinoma cells were injected into the subcutaneous tissue at a final concentration of 10 7 cells in 0.1 ml of PBS (n ¼ 12 mice per group). Tumor growth was monitored over a period of 30 days by measurement with a caliper, and tumor volumes were calculated.
Endothelial cell migration assay
The endothelial cell migration assay was performed as previously described (Lingen, 2002) . Briefly, human dermal microvascular endothelial cells (Cell Systems, Kirkland, WA, USA) were starved overnight in media containing 0.1% BSA, harvested, resuspended into DME with 0.1% BSA, plated on the bottom side of a modified Boyden chamber (Nucleopore Corporation, MD, USA), and allowed to attach in the inverted chamber for 2 h at 371C. The chamber was then re-inverted, test substances (1 mg total protein per test compound in a volume of 50 ml) added to the wells of the upper chamber, and cells were allowed to migrate for 4 h at 371C. Membranes were recovered, fixed, stained, and the number of cells that had migrated to the upper chamber per 10 high power fields counted. Each substance was tested in quadruplicate in each experiment and all experiments were repeated at least twice. VEGF (R&D Systems, MN, Minnesota, USA) was used as a positive control at a concentration of 200 pg/ml.
For functional validation migration studies of VEGF and TSP-1, neutralizing antibodies were used at the following concentrations: anti-VEGF (R&D Systems, Minneapolis, MN, USA; Catalog #: AF-293-NA; 20 mg/ml) and anti-TSP-1 (Lab Vision, Fremont, CA, USA; Catalog #: MS-418-P1ABX; 20 mg/ml). Optimal concentrations for growth factors and antibodies were determined previously by dose-response experiments (data not shown). All antibodies were tested alone and found to be neutral in that they neither stimulated nor reduced basal levels of migration, indicating that the doses used were neither stimulatory nor toxic (data not shown).
Histology
For CD31 detection, the primary antibody (PECAM-1, BD Pharmigen, San Jose, CA, USA; Catalog #: 550274) was applied to deparaffinized sections at a 1:100 dilution in PBS for 6 h at 41C. The biotinylated secondary antibody (Dako Labeled Streptavidin-Biotin kit, Carpinteria, CA, USA; Catalog #: x0590) was applied for 30 min, washed and the enzyme conjugate was added for 30 min. For VEGF detection, deparaffinized sections were microwaved in citrate buffer, rabbit primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA; Catalog #: sc-152) was applied at a dilution of 1:100 for 1 h at room temperature, and the rabbit EnVision þ kit (DAKO, Carpinteria, CA, USA) was used for detection. For determination of cell proliferation, sections were microwaved in citrate buffer and incubated in a 1:1 dilution of PCNA antibody (Zymed, San Francisco, CA, USA; Catalog #: 93-1143) for 1 h. Apoptotic cells were detected using an antibody to cleaved caspase-3 (Biocare Medical, Walnut Creek, CA, USA; Catalog number: CP229A). Pretreatment for caspase was achieved by using a decloaker with ET buffer. HRP-conjugated secondary antibody to rabbit (Envision þ , DAKO, Carpenteria, CA, USA; Catalog #: K4010) was used with incubation for 30 min each. For thrombospondin, a 1:100 dilution of anti-TSP-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; Catalog #: sc-12312) was used to incubate sections overnight at 41C, followed by incubation with a secondary antibody (Dako Labeled Streptavidin-Biotin kit, Carpinteria, CA, USA; Catalog #: x0590) and streptavidin horseradish peroxidase. All sections were counterstained with hematoxylin.
Quantification of immunohistochemistry
To quantitate proliferation, apoptosis and CD31 staining, the sections were first scanned at low power ( Â 40) to avoid counting areas that contained necrosis. The proliferating and apoptotic cells were counted at high power ( Â 400) and expressed as a percentage of the total number of cells. Determination of microvessel density using the CD31-stained slides was performed as described previously (Lingen et al., 1998) . Briefly, the region containing the most intense area of tumor neovascularization was chosen for counting in each of the tumors. Individual microvessels were counted using an Â 200 field ( Â 20 objective lens and Â 10 ocular lens). Any brown-staining endothelial cells that were clearly separate in appearance were counted as individual vessels. Results were expressed as the highest number of microvessels observed at Â 200 in the 'hot spot' region of each individual tumor.
